Overview

Relative Bioavailability of Olodaterol and Fluconazole

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fluconazole
Olodaterol